VETMEDIN-CA1 (pimobendan) chewable tablets is conditionally approved for the treatment of dogs with myxomatous mitral valve disease (MMVD) in the pre-clinical stage B2 (asymptomatic with a murmur/abnormal heart sounds and evidence of increased heart size) to delay onset of clinical signs of heart failure. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-556.
Who is Vetmedin-CA1 (pimobendan) Chewable Tablets for Dogs for?
For use in dogs 6 months of age or older diagnosed with myxomatous mitral valve disease (MMVD) at a stage known as B2 (asymptomatic with a murmur and evidence of increased heart size).
Why use Vetmedin-CA1 (pimobendan) Chewable Tablets for Dogs?
Recommended for dogs diagnosed with Stage B2 MMVD, VETMEDIN®-CA1 (pimobendan) can be used for the delay of onset of congestive heart failure. May prolong the number of symptom-free days in dogs. VETMEDIN-CA1 helps dogs continue to engage in the daily activities they enjoy. Available as a beef-flavored, chewable tablet in 2 convenient dosing sizes (1.25 mg and 5 mg).
How does Vetmedin-CA1 (pimobendan) Chewable Tablets for Dogs work?
The active ingredient in VETMEDIN®-CA1 (pimobendan) helps the heart muscle to contract and relax (pump) more effectively and it dilates blood vessels which reduces the amount of force with which the heart needs to pump blood.
How is Vetmedin-CA1 (pimobendan) Chewable Tablets for Dogs sold?
Sold in 50 count chewable tablet bottles in strengths of 1.25 mg or 5 mg.
What are the side effects of Vetmedin-CA1 (pimobendan) Chewable Tablets for Dogs?
The most common side effects seen in dogs with Stage B2 MMVD while taking VETMEDIN®-CA1 Chewable Tablets are cough, vomiting, diarrhea, lethargy (lack of energy), and localized pain (such as in the neck or legs). VETMEDIN®-CA1 may cause side effects, even at the prescribed dose. Contact your veterinarian immediately if your dog develops a serious or concerning medical problem or side effect while taking VETMEDIN®-CA1. The safety of VETMEDIN®-CA1 has not been established in puppies younger than 6 months of age, or in breeding, pregnant or lactating dogs.
What special precautions are there?
VETMEDIN®-CA1 (pimobendan) Chewable Tablets is only for use in dogs diagnosed with myxomatous mitral valve disease (MMVD) at a stage known as B2 (asymptomatic with a murmur and evidence of increased heart size). VETMEDIN®-CA1 is not for use in humans: keep this and all medications out of reach of children and consult a physician in case of accidental ingestion. VETMEDIN®-CA1 should only be used in accordance with instructions from your veterinarian.
Contact your nearest emergency animal hospital.
How can I store Vetmedin-CA1 (pimobendan) Chewable Tablets for Dogs?
Store at 20° to 25°C (68° to 77°F), excursions permitted between 15° and 30°C (between 59° and 86°F).
Use as directed by your Veterinarian. Dosage Instructions/Directions: VETMEDIN®-CA1 (pimobendan) Chewable Tablets should be administered orally at a total daily dose of 0.23 mg/lb (0.5 mg/kg) body weight, using a suitable combination of whole or half tablets. The total daily dose should be divided into 2 portions that are not necessarily equal, and the portions should be administered approximately 12 hours apart (i.e., morning and evening). The tablets are scored, and the calculated dosage should be provided to the nearest half tablet increment.